KRRO
Korro Bio, Inc.
1W: -16.0%
1M: -8.1%
3M: +35.9%
YTD: +33.5%
1Y: -54.7%
3Y: -64.5%
5Y: -99.5%
$10.75
-0.31 (-2.80%)
After Hours: $10.91 (+0.16, +1.53%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$106.6M
52W Range5.204-55.89
Volume179,981
Avg Volume241,130
Beta2.54
Dividend—
Analyst Ratings
Company Info
CEORam Aiyar
Employees112
SectorHealthcare
IndustryBiotechnology
IPO Date2019-10-03
Websitekorrobio.com
One Kendall Square
Cambridge, MA 02139-1562
US
Cambridge, MA 02139-1562
US
781-315-4600
About Korro Bio, Inc.
Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts.
Latest News
Korro Bio Stock Gains After Tough 2025 - New Drug Candidate, Analyst Upgrades Boost Outlook
12 Health Care Stocks Moving In Friday's Pre-Market Session
Korro Bio, Inc. (KRRO) Reports Q4 Loss, Lags Revenue Estimates
12 Health Care Stocks Moving In Thursday's After-Market Session
Korro Bio GAAP EPS of -$12.48 misses by $3.43, revenue of $6.4M beats by $1M
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Yang Rick | P-Purchase | 207,100 | $11.11 | 2026-03-10 |
| Yang Rick | P-Purchase | 242,945 | $0.00 | 2026-03-10 |
| SANDELL SCOTT D | P-Purchase | 207,100 | $11.11 | 2026-03-10 |
| SANDELL SCOTT D | P-Purchase | 242,945 | $0.00 | 2026-03-10 |
| New Enterprise Assoc | P-Purchase | 207,100 | $11.11 | 2026-03-10 |